Magnetometer guided detection of sentinel lymph nodes in prostate cancer after transrectal injection of superparamagnetic iron oxide particles

Magnetometer guided detection of sentinel lymph nodes in prostate cancer after transrectal injection of superparamagnetic iron oxide particles - SentiMagPro

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00005473

Enrollment

Registered

2013-11-26

Start date

2013-12-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Prostate cancer patients (PSA greater than 10 ng/ml, Gleason score greater than or equal to 7), which are receiving a radical retropubic prostatectomy, a magnetometer (SentiMag) guided sentin

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Prostate cancer, PSA greater than 10, Gleason score graeter or equal to 7

Exclusion criteria

Exclusion criteria: Intolerance / hypersensitivity to iron or dextran or Sienna +, patients with iron overload disease, cardiac pacemakers or other in the chest wall implanted devices

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the detection of at least one sentinel lymph node by the SentiMag system per patient.	—

Secondary

Measure	Time frame
Sensitivity of the magnetometer guided lymphadenectomy in the detection of lymph node metastases	—

Countries

Germany

Contacts

Public ContactAlexander Winter

Universitätsklinik für Urologie, Klinikum Oldenburg

winter.alexander@klinikum-oldenburg.de04414032304

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 19, 2026